Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics

Biotechnology Research

Kiryat Aryeh, Petach Tikva 6,030 followers

About us

BrainStorm Cell Therapeutics Inc. (NASDAQ) develops autologous stem cell therapies for neurodegenerative disorders such as ALS, MS, and Parkinson’s disease. These diseases have limited treatment options and represent unmet medical needs. NurOwn® is BrainStorm’s proprietary process for differentiating autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, transplanted at or near the affected tissue site. Our technology converts MSCs into a living drug delivery system for NTFs. We have proof-of-concept in various animal models of neurodegenerative diseases, including Parkinson's, Huntington's, ALS, MS, and peripheral nerve injury. We have completed two single-arm clinical trials in ALS patients in Israel, demonstrating good safety and tolerability profiles and strong efficacy signals. We also finalized a Phase 3 randomized, double-blind, placebo-controlled clinical trial at multiple US sites, supported by a $16 million USD grant from the California Institute for Regenerative Medicine (CIRM) and another grant from the ALS Association. Currently, we are planning a Phase 3b clinical trial of NurOwn® in ALS under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). For more information, visit www.brainstorm-cell.com

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Kiryat Aryeh, Petach Tikva
Type
Public Company
Founded
2004
Specialties
stem cell therapy, drug development, neurodegenerative diseases, and ALS

Locations

  • Primary

    12 Bazel Street

    POB 10019

    Kiryat Aryeh, Petach Tikva 49001, IL

    Get directions
  • 3 University Plaza Drive

    Suite 320

    Hackensack, NJ 07601, US

    Get directions

Employees at Brainstorm Cell Therapeutics

Updates

Similar pages

Browse jobs

Funding